CDR132L

About Cardior Pharmaceuticals

Cardior Pharmaceuticals is a private, clinical-stage biotech based in Hannover, Germany, focused on developing first-in-class RNA therapeutics for heart disease. The company's core platform utilizes non-coding RNAs to halt and reverse detrimental cardiac remodeling, with its lead asset CDR132L currently in a Phase 2 clinical trial (HF-REVERT) for post-myocardial infarction heart failure. Founded by renowned cardiology researcher Prof. Thomas Thum, Cardior aims to create a paradigm shift in cardiology treatment by targeting underlying disease mechanisms rather than just symptoms. The company is pre-revenue and positioned in a large, underserved market with significant unmet need.

Therapeutic Areas